Tisotumab vedotin is currently in clinical development for the treatment of patients with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy. Cervical cancer develops in a woman’s cervix (lower part of the womb). It mainly affects sexually active women aged between 30 and 45 years. Cervical cancer often has no symptoms in its early stages. Cervical cancer that has spread to another part of the body is called advanced or metastatic cancer. Cancer that returns after months or years of the completion of the initial treatment is called recurrent cancer. The most common symptom of cervical cancer includes bleeding from the vagina at times other than the usual periods. Despite the recent developments, the prognosis remains poor and systemic therapy options are needed for women with recurrent and metastatic cervical cancer.
Tisotumab vedotin is administered by intravenous infusion. It is an antibody-drug conjugate that binds to tissue factor (TF), a protein expressed on the cell surface of tumour cells. This then induces cancer cells death. If licenced tisotumab vedotin will offer a treatment option for adult females with recurrent or metastatic cervical cancer who have received at least one prior systemic therapy.
Pembrolizumab is an immunomodulatory medicinal product, meaning that it helps the immune system to recognise and attack cancer cells. It is administered by intravenous infusion and is currently licensed in the UK for melanoma, non-small cell lung cancer and urothelial cancer – amongst others. If licensed, pembrolizumab, in addition to chemotherapy, would offer an alternative treatment for those with advanced, recurrent or metastatic cervical cancer.